Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan, Paclitaxel, and Carboplatin in Advanced Ovarian Cancer
NCT00193297Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Feb 2002
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of topotecan in ovarian carcinoma and primary peritoneal carcinoma (PPC), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate. Started Feb 2002; status: completed.
02
Drugs
topotecan
03
Conditions
ovarian carcinomaprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00193297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193297.